Spots Global Cancer Trial Database for gemox chemotherapy
Every month we try and update this database with for gemox chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | NCT04961788 | Intrahepatic Ch... | Gemox combimed ... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04669496 | Intrahepatic Ch... PD1 Antibody Lenvatinib Gemox Chemother... | Neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma | NCT04361331 | Cholangiocarcin... | Lenvatinib comb... Toripalimab com... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04669496 | Intrahepatic Ch... PD1 Antibody Lenvatinib Gemox Chemother... | Neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital |